fbpx

molecules of the month

“compound 2”

potent, oral heme-displacing IDO1 inhibitor

low predicted human dose (<10 mg QD)

from ALIS mass-based binding screen + SBDD

ACS Med. Chem. Lett., Jul. 15, 2020

Merck & Co., Boston, MA

Structure of compound 2
1 min read

“compound 2” is a heme-displacing IDO1 inhibitor with a similar binding mode to BMS-986205 with a low projected human dose. A bis-amide hit was generated from a mass-spectrometry based binding screen, and optimized through structure-based drug design. An initial benzamide lead was metabolically unstable due to rapid amide hydrolysis, but this was addressed by replacing a central phenyl ring with the bicyclo[1.1.1]propane (BCP) motif. While the BCP has been touted as a phenyl isostere, it is rare to see central phenyl groups replaced without significant losses in activity. Impressively, the BCP replacement led to a substantially improved series of molecules for the Merck team, convincing me to try this move more often!


request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.


already a member? log in: